RxDoctor Payments Data

Katie Creighton, NP

Family · Annapolis, MDNPI 1467717298

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 421 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,678in general payments, 2019–2025

Across 421 payments — averaging $22.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Novo Nordisk$563
  • Amgen$551
  • GSK$544
  • Bayer$501
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$9,61899%
  • Education$601%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie76$1,289
AstraZeneca(2 entities)27$1,122
Novo Nordisk25$563
Amgen(2 entities)29$551
GSK21$544
Bayer23$501
Pfizer23$501
Sumitomo Pharma America, Inc.14$437
Otsuka America Pharmaceutical, Inc.9$277
Lilly USA, LLC12$249
Astellas Pharma US Inc9$224
Biohaven Pharmaceuticals, Inc.6$216
Boehringer Ingelheim11$194
Novartis10$189
Nevro Corp.5$186
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$170
Harmony Biosciences LLC3$160
Sunovion Pharmaceuticals Inc.9$158
Biogen6$142
Corcept Therapeutics6$139
Teva Pharmaceuticals USA, Inc.6$135
Kowa Pharmaceuticals America, Inc.7$116
Esperion Therapeutics, Inc.5$114
Urovant Sciences Inc1$107
Axsome Therapeutics, Inc.4$101
Lundbeck LLC5$93
Merck4$83
Shield Therapeutics Inc4$66
Silk Road Medical, Inc.2$66
Amneal Pharmaceuticals LLC4$64
Idorsia Pharmaceuticals US Inc3$63
Mylan Specialty L.p.3$57
Phathom Pharmaceuticals, Inc.4$55
Vanda Pharmaceuticals Inc.2$53
Genentech USA, Inc.3$51
Acadia Pharmaceuticals Inc2$50
Biohaven Pharmaceutical Holding Company Ltd.2$43
Organogenesis Inc.1$42
Eisai Inc.2$42
Xeris Pharmaceuticals, Inc.2$35
Digestive Care, Inc.1$33
Amarin Pharma, Inc.2$33
Inspire Medical Systems, Inc.1$29
Gilead1$26
Kyowa Kirin, Inc.1$24
Verona Pharma, Inc.1$23
Phadia US Inc.1$22
Neos Therapeutics, LP1$20
Dexcom, Inc.1$20
Takeda Pharmaceuticals U.S.A., Inc.1$19
Abbott1$18
Johnson & Johnson1$18
Eyevance Pharmaceuticals LLC1$18
Hikma Pharmaceuticals USA1$18
TMS Neurohealth Centers Inc.1$17
Corium, LLC1$17
Ironwood Pharmaceuticals, Inc1$16
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$15
Avanir Pharmaceuticals, Inc.1$15
Currax Pharmaceuticals LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,678 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$90,412
Medicare patients
310
Services billed
1,185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban31$26,784
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$22,105
FarxigaDapagliflozin Propanediol18$20,918
JardianceEmpagliflozin22$20,597
TrulicityDulaglutide14$13,493
Rosuvastatin Calcium68$1,227
RivastigmineRivastigmine Tartrate22$1,096
Albuterol Sulfate HfaAlbuterol Sulfate34$797
Atorvastatin Calcium70$715
Levothyroxine Sodium52$532
Valsartan14$507
Losartan Potassium39$491
Famotidine44$482
Fluticasone Propionate27$462
Alprazolam27$456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$501$26,78431 claims
GSKTrelegy Ellipta$544$22,10530 claims
AstraZenecaFarxiga$1,122$20,91818 claims
Boehringer IngelheimJardiance$194$20,59722 claims
Lilly USA, LLCTrulicity$249$13,49314 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$64$53252 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.

Other family in Annapolis

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →